Abstract:Studies indicate that breast tissue has a distinct modifiable microbiome population. However, whether endocrine-targeting therapies modify the non-cancerous breast microbiome to impact tumorigenesis is unknown. To examine this question, we performed 16S bacterial sequencing on DNA isolated from female C57BL/6 mouse mammary glands (MG) administered tamoxifen citrate for 16 weeks and breast tissue from ovariectomized non-human primates administered tamoxifen citrate (TAM) for 2.5 years. In both models, we show that TAM significantly shifted β-diversity and increased Firmicutes proportional abundance. TAM elevated the proportional abundance of Lactobacillus spp., Streptococcus luticea, and Staphylococcus sciuri. Female BALB/c mice received intra-nipple injections of Lactobacillus and MG were harvested at 1-, 3-, 7-, and 14-days post-injection to show bacteria colonization and modulation of metabolism-associated gene and protein expression. B6.MMTV-PyMT mice were injected with Lactobacillus bacteria into the MG. Elevating MG Lactobacillus reduced tumorigenesis with an associated decrease in tumor proliferation and shifts in non-cancerous MG tissue metabolism. To elucidate the effects of combining TAM and probiotic bacteria on breast cancer outcomes, 4T1.2ER+ tumor-bearing female BALB/c mice, fed either a control or Western diet were treated with TAM, Lactobacillus probiotic, or a combination of TAM + Lactobacillus. Results indicate that oral probiotic administration in combination with TAM reduced ER+ tumor growth. Plasma metabolomics revealed combination treatment elevated L-carnitine regardless of diet, suggesting drug-bug interactions modifying metabolite profiles. Cell viability assays on human MCF7 BC cells and non-cancerous mammary HMT-3522S1 cells treated with 1% probiotic-conditioned media (Pro-CM) revealed a significant decrease in cell viability in BC cells but not non-cancerous epithelial cells. Mitochondrial fuel oxidation Seahorse assay on murine 4T1.2ER+ cells treated with 1% Pro-CM, 1μm 4-hydroxytamoxifen (4-OHT) or combination revealed changes in metabolic substrate dependency, supporting role of microbial metabolites impacting metabolism. Tumor sections from patients with ER+ BC treated with aromatase inhibitors and/or Faslodex in the neoadjuvant setting were stained for Gram-positive bacteria, Gram-negative bacteria, and Ki67. Gram-positive bacteria negatively correlated with Ki67 immunoreactivity, suggesting endocrine-targeting therapies promote tumor Gram-positive bacteria associated with a decrease in proliferation. Taken together, our data indicates that endocrine-targeting treatments modify the breast microbiome associated with a shift in tissue metabolism to decrease proliferation and reduce ER+ BC risk. Citation Format: Alana Arnone, Yu-Ting Tsai, J Mark Cline, Adam S. Wilson, Brian Westwood, Meghan E. Seger, Akiko Chiba, Marissa Howard-McNatt, Edward A. Levine, Alexandra Thomas, David R. Soto-Pantoja, Katherine L. Cook. Endocrine-targeting therapies modify the breast microbiome to shift metabolism and reduce cancer risk [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2181.

Effect of 2‐methoxyestradiol treatment on early‐ and late‐stage breast cancer progression in a mouse model

Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells

2-methoxyestradiol inhibits the malignant behavior of triple negative breast cancer cells by altering their miRNome

2-Methoxyestradiol (2-ME2, Panzem®) and Its New Derivatives Inhibited Lung Cancer Cells in Vitro and in Vivo

In vitro effects of 2-methoxyestradiol-bis-sulphamate on reactive oxygen species and possible apoptosis induction in a breast adenocarcinoma cell line

[Effect of 2-Methoxyestradiol on Proliferation and Apoptosis of Myeloma Cell Lines].

Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat

Inhibition on Liver Metastases of Colon Cancer in Nude Mice by Angiogenesis Inhibitor 2-Methoxyestradiol

Synergism between the Anticancer Actions of 2-Methoxyestradiol and Microtubule-Disrupting Agents in Human Breast Cancer

Effect of honey bee venom on proliferation of K1735M2 mouse melanoma cells in-vitro and growth of murine B16 melanomas in-vivo.

Adverse effects of 2-Methoxyestradiol on mouse oocytes during reproductive aging

2-Methoxyestradiol: A Hormonal Metabolite Modulates Stimulated T-Cells Function and proliferation

Methylseleninic Acid Restricts Tumor Growth in Nude Mice Model of Metastatic Breast Cancer Probably Via Inhibiting Angiopoietin-2

2-Methoxyestradiol Inhibits the Proliferation and Migration and Reduces the Radioresistance of Nasopharyngeal Carcinoma CNE-2 Stem Cells Via NF-κB/HIF-1 Signaling Pathway Inactivation and EMT Reversal.

Nutritional combinatorial impact on the gut microbiota and plasma short-chain fatty acids levels in the prevention of mammary cancer in Her2/neu estrogen receptor-negative transgenic mice

Abstract 2181: Endocrine-targeting therapies modify the breast microbiome to shift metabolism and reduce cancer risk

Effect of 2-Methoxyestradiol on Apoptosis of Bone Marrow Cells of Patients with Multiple Myeloma

Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study

2-Methoxyestradiol-bis-sulfamate induces apoptosis and autophagy in a tumorigenic breast epithelial cell line

P38 Mitogen-activated Protein Kinases is Required for Counteraction of 2-Methoxyestradiol to Estradiol-Stimulated Cell Proliferation and Induction of Apoptosis in Ovarian Carcinoma Cells Via Phosphorylation Bcl-2

High Oral Bioavailability of 2-Methoxyestradiol in PEG-PLGA Micelles-Microspheres for Cancer Therapy